Nebojsa Milovic

Novartis (Switzerland)

Papers

1

Total Citations

47

H-Index

1

About

Dr. Nebojsa Milovic is a leading figure in biopharmaceutical formulation science, with a primary focus on the high-throughput development of therapeutic antibodies. His most cited work, "Formulation Development of Antibodies Using Robotic System and High-Throughput Laboratory (HTL)" (2009, 47 citations), represents a seminal contribution to the field. In this study, Dr. Milovic pioneered the integration of robotic automation and miniaturized high-throughput screening to accelerate the traditionally slow, labor-intensive process of antibody formulation. By demonstrating how HTL platforms can rapidly assess protein stability, viscosity, and aggregation across hundreds of conditions, he provided the pharmaceutical industry with a blueprint for drastically reducing development timelines. This work has been instrumental in enabling faster clinical translation of biologic drugs, directly impacting how major biotech firms approach formulation design. Dr. Milovic’s research bridges the gap between engineering and protein chemistry, establishing him as a key innovator in the automation of biologics development. His contributions continue to influence both academic research and industrial best practices, making him a vital resource for students and researchers seeking to understand modern, data-driven approaches to drug product development.

Research Focus

Key Achievements

1
H-Index
1
Papers
47
Total Citations
47
Avg Citations/Paper
🏆 Most Cited Paper
Formulation Development of Antibodies Using Robotic System and High-Throughput Laboratory (HTL)
47 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Novartis (Switzerland)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago